Therapeutic antibodies and related products: Choosing the right structure for success;Anticorps thérapeutiques et dérivés: Une palette de structures pour une pléthore d'indications - Quel format et quelle glycosylation choisir? Pour quelles applications?

Medecine/Sciences

Volumn 25, Issue 12, 2009, Pages 1024-1032

  Beck, Alain ^a   Wagner Rousset, Elsa ^a   Wurch, Thierry ^a   Corvaia, Nathalie ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74749108425     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121024     Document Type: Review

References (48)

1. Schneider CK. Monoclonal antibodies: regulatory challenges. Current Pharmaceutical Biotechnology 2008 ; 9 : 431-8.
2. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression system: an overview of the current upstream technologies. Curr Pharm Biotechnol 2008 ; 9 : 447-67.
3. Seamans TC, Fries S, Beck A, et al. Cell cultivation process transfer and scale up in support of the production of early clinical supplies of an anti-IGF-1R antibody (part I). BioProcess Int 2008 ; 3 : 26.
4. Beck A, Klinguer-Hamour C, Bussat MC, et al. Peptides as tools and drugs for immunotherapies. J Pept Sci 2007 ; 13 : 588-602.
5. Beck A, Wagner-Rousset E, Goetsch L, et al. Therapeutic antibodies: structure assessment by mass spectrometry from screening to clinical batches. Screening Trends Drug Discov 2008 ; 9 : 18-20.
6. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008 ; 9 : 423-30.
7. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins. Curr Pharm Biotechnol 2008 ; 9 : 482-501.
8. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 ; 256 : 495-7.
9. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984 ; 81 : 6851-5.
10. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986 ; 321 : 522-5.
11. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990 ; 348 : 552-4.
12. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994 ; 368 : 856-9.
13. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994 ; 7 : 13-21.
14. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, et al. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008 ; 3 : 1157-71.
15. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008 ; 20 : 450-9.
16. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008 ; 20 : 436-3.
17. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007 ; 7 : 1401-13.
18. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007 ; 25 : 1369-72.
19. Van der Neut Kolfschoten M., Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007 ; 317 : 1554-7.
20. Dillon TM, Ricci MS, Vezina C, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008 ; 283 : 16206-15.
21. Yoo EM, Wims LA, Chan LA, et af. Human IgG2 can form covalent dimers. J Immunol 2003 ; 170 : 3134-8.
22. Liu YD, Chen X, Enk JZ, et al. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008 ; 283 : 29266-72.
23. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008 ; 20 : 460-70.
24. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 ; 25 : 1256-64.
25. Natsume A, In M, Takamura H, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008 ; 68 : 3863-72.
26. Angal S, King DJ, Bodmer MW, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993 ; 30 : 105-8.
27. Kai M, Motoki K, Yoshida H, et al. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nat Biotechnol 2008 ; 26 : 209-11.
28. Wurch T, Lowe P, Caussanel V, et al. Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation. Curr Pharm Biotechnol 2008 ; 9 : 502-9.
29. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008 ; 358 : 1109-17.
30. Wagner-Rousset E, Bednarczyk A, Bussat MC, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2008 ; 872 : 23-37.
31. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006 ; 6 : 1161-73.
32. Hamilton SR, Gerngross TU. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007 ; 18 : 387-92.
33. Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008 ; 320 : 373-6.
34. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008 ; 20 : 471-8.
35. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008 ; 20 : 479-85.
36. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008 ; 7 : 641-2.
37. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008 ; 26 : 985-90.
38. Moon Jy, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blacker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008 ; 49 : 389-99.
39. Beck A, Bussat MC, Zorn N, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NSO cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005 ; 819 : 203-18.
40. Vlasak J, Ionescu R. Heterogeneity of Monoclonal Antibodies relvealed by charge-sensitive methods. Curr Pharm Biotechnol 2008 ; 9 : 468-81.
41. Beck A, Wurch T, Corvaïa N. Editorial: therapeutic antibodies and derivatives: from the bench to the clinic. Curr Pharm Biotechnol 2008 ; 9 : 421-2.
42. Swann PG, Tolnay M, Muthukkumar S, et al. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008 ; 20 : 493-9.
43. Kim MS, Lee SH, Song MY, et al. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 2007 ; 374 : 1374-88.
44. Aggarwal S. What's fueling the biotech engine-2007. Nat Biotechnol 2008 ; 26 : 1227-33.
45. Gires O. EpCAM, une protéine versatile impliquée dans l'oncogenèse. Med Sci (Paris) 2009 ; 25 : 449-50.
46. Faye L, Champey Y. Plantes, médicaments et génétique : quelles applications pour demain ? Med Sci (Paris) 2008 ; 24 : 939-45.
47. Beck A, Iver H, Reichert JM. European Medecines Agency workshop on biosimilar monoclonal antibodies Meeting Report (London, UK, July 2, 2009). mAbs-Landes Bioscience 2009 ; 5 : 394-416. (http://www.landesbioscience. com/journals/mabs/article/9630).
48. Beck A, Cochet O, Wurch T. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Op Drug Discov 2010 (sous presse).